Hemoptysis

Distinguishing Hemoptysis from Mimics

Pathophysiology: Vascular Origin

Etiology

Airway Causes

• Acute/chronic bronchitis - most common cause overall in developed countries (blood-streaked sputum)
• Bronchiectasis - major source of massive hemoptysis; distorted, hypertrophied bronchial vessels
• Bronchogenic carcinoma - accounts for a large proportion of cases; up to 20% of lung cancer patients have hemoptysis at some point
• Endobronchial metastases - from carcinoid tumors, breast, colon, renal, melanoma
• Carcinoid tumor - biopsy can cause impressive hemorrhage
• Foreign body

Parenchymal/Infectious Causes

• Tuberculosis - leading cause worldwide; destruction of lung parenchyma ruptures blood vessels; cavitary TB can erode into pulmonary artery forming a Rasmussen aneurysm with potentially fatal hemorrhage
• Pneumonia - bacterial, viral
• Lung abscess
• Aspergillosis/fungal infections - especially in immunocompromised patients; cavitary lesions after granulocytopenia resolves
• Bronchiectasis (post-TB, cystic fibrosis)
• Parasitic: Paragonimus (lung fluke from infected crustaceans), Echinococcus (hydatid cysts)

Vascular Causes

• Pulmonary embolism with infarction (usually not massive)
• Mitral stenosis - pulmonary venous hypertension
• Arteriovenous malformations (Osler-Weber-Rendu / HHT - friable telangiectasias)
• Pulmonary artery pseudoaneurysm (Rasmussen aneurysm in TB cavities)

Inflammatory/Autoimmune

• Granulomatosis with polyangiitis (formerly Wegener's) - associated with saddle nose deformity, hematuria
• Goodpasture syndrome - anti-GBM antibody disease; ask about hematuria/renal insufficiency
• Diffuse alveolar hemorrhage - from vasculitis, bone marrow transplantation chemotherapy

Other Causes

• Iatrogenic - Swan-Ganz catheter injury, bronchoscopic biopsy, lung biopsy
• Trauma - deceleration injuries, penetrating thoracic trauma
• Tracheoinnominate fistula - erosion of tracheostomy into the innominate artery (catastrophic)
• Aortobronchial fistula - aortic aneurysm erosion into airway
• Catamenial - cyclical hemoptysis with menstruation (pulmonary endometriosis)
• Drug/toxic - cocaine/heroin inhalation, nitrogen dioxide exposure (diffuse alveolar hemorrhage); bevacizumab/ramucirumab (VEGF inhibitors) increase risk especially in squamous cell NSCLC with cavitary lesions
• Cryptogenic - ~30% historically; CT has reduced this proportion

Age/smoking rule of thumb: Hemoptysis before middle age: think infections. After age 40-45 or with smoking history: bronchogenic carcinoma leads the differential. - Fishman's Pulmonary Diseases and Disorders

Classification by Severity

Clinical Evaluation

History

• Smoking history, duration, pack-years
• Travel or emigration from TB-endemic regions (Africa, Southeast Asia, Eastern Europe, Middle East, inner-city areas)
• History of structural lung disease (bronchiectasis, COPD, cystic fibrosis)
• Fever, weight loss, night sweats (TB, malignancy)
• Hematuria or renal disease (Goodpasture's, GPA)
• Anticoagulant use, recent procedures
• Cyclical timing with menstruation (catamenial/endometriosis)
• Drug use (cocaine, heroin inhalation)

Physical Examination

• Examine sputum directly (blood-streaked vs. frank blood/clots)
• Oral cavity and nasopharynx (exclude epistaxis, gingival bleeding)
• Lung auscultation: rales, bronchial breath sounds, amphoric sounds over cavities
• Clubbing (chronic suppurative disease, malignancy)
• Saddle nose deformity (GPA)
• Telangiectasias on lips/tongue (HHT/Osler-Weber-Rendu)
• Signs of DVT/PE

Investigations

Initial Workup

• Chest X-ray - insensitive for lateralizing/identifying source, especially in mild hemoptysis; useful as a starting point
• CBC (anemia from chronic blood loss, thrombocytopenia)
• Coagulation studies (PT, INR, aPTT)
• Renal function + urinalysis (GPA, Goodpasture's)
• Sputum AFB (TB smear/culture)

CT Chest

• CT chest with IV contrast / CT angiography - visualizes bronchial/nonbronchial systemic arteries and the pulmonary circulation
• Identifies bronchial artery hypertrophy (diameter ≥2-3 mm), tortuous vessels, aneurysm formation, pleural thickening adjacent to parenchymal disease
• Preferred over plain CT in massive hemoptysis for procedural planning
• Indications for CT: suspected malignancy, bronchiectasis/cavitary disease, candidates for embolization

Bronchoscopy

• Role is controversial in non-massive hemoptysis - does not increase diagnostic yield beyond CT
• In massive hemoptysis: early bronchoscopy (during active bleeding or within 48 hours) can localize the bleeding source and guide embolization
• Current recommendation: MDCT before bronchoscopy in most cases of massive hemoptysis
• Allows direct therapeutic interventions: clot clearance, Nd:YAG laser, argon plasma coagulation (APC), electrocautery, topical hemostatic tamponade

Management

Mild Hemoptysis

• Identify and treat the underlying cause
• Acute bronchitis: antibiotics if bacterial
• Arrange follow-up with pulmonologist if structural disease or malignancy suspected
• Most cases are self-limited with conservative management

Fig. 63-1. Mild hemoptysis workup algorithm - Tintinalli's Emergency Medicine

Massive Hemoptysis - Emergency Management

Step 1: Airway Control

1. Position the patient - lateral decubitus with bleeding side DOWN to prevent aspiration into the unaffected lung
2. If intubation required: use large-bore ETT (to allow bronchoscopy)
3. If the bleeding side is known and uncontrollable: selective right (or left) main bronchus intubation of the unaffected lung to protect it
4. Fogarty catheter (14F/100 cm) can be used to tamponade the affected bronchus
5. Tracheoinnominate fistula (from tracheostomy erosion): immediate digital pressure on the anterior trachea through the tracheostomy site against the posterior sternum - emergency surgical consultation

Step 2: Investigations

• MDCT chest angiography (after stabilization) to localize and plan intervention
• Multidisciplinary consultation: pulmonology + interventional radiology + cardiothoracic surgery + ICU

Step 3: Definitive Bleeding Control

• Harrison's 22E (2025): BAE is considered the first-line definitive procedure; controls brisk bleeding in 75-90%, allowing safer definitive surgery if appropriate.
• Tintinalli's: BAE followed by bronchoscopy if necessary is the initial and most effective treatment of massive and recurrent hemoptysis.

Special Situations

• Aspergillosis-related cavitary lesions in hematologic malignancy: Cavitation after granulocytopenia resolves can cause massive hemoptysis; correct thrombocytopenia/coagulopathy; surgical evaluation recommended
• Bevacizumab/ramucirumab (VEGF inhibitors): Contraindicated in NSCLC patients with squamous histology, cavitary lesions, or prior hemoptysis ≥2.5 mL in the past 3 months due to high risk of pulmonary hemorrhage
• Pulmonary embolism with infarction: Hemoptysis generally does not pose increased major bleeding risk, but underlying conditions like bronchiectasis or lung cancer may significantly increase risk; vena cava filter may be warranted if anticoagulation risk is high

Disposition

• Mild, self-limited hemoptysis with normal CXR and no risk factors: outpatient PCP or pulmonologist follow-up
• Any severe hemoptysis, hemodynamic/respiratory instability, or high-risk etiology: ICU admission or transfer to tertiary care center

Key Clinical Pearls

1. ~30% of hemoptysis cases were historically cryptogenic; MDCT has substantially reduced this.
2. Bronchial (not pulmonary) artery is the source of most life-threatening hemoptysis due to high systemic perfusion pressure.
3. TB is the leading cause worldwide; bronchogenic carcinoma leads after age 40-45 with smoking history.
4. Rasmussen aneurysm = pulmonary artery pseudoaneurysm from erosion of TB cavity wall - potentially fatal.
5. Tracheoinnominate fistula from tracheostomy = catastrophic; first-line control is digital pressure.
6. BAE controls 75-90% of massive hemoptysis but carries 20-50% rebleeding risk without definitive surgical correction of the underlying cause.
7. A recent 2025 systematic review on nebulized tranexamic acid for hemoptysis (PMID 39841268) supports its emerging role in hemoptysis management.